Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...

GuruFocus.com11-09

Revenue: $7 million, an increase of 10.2% year-over-year. Therapeutic Device Revenue: $6.5 million, up 8.5% driven by PulseVet's 24.5% growth. Diagnostics Segment Revenue: Approximately $500,000, an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482347874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 03:02","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482347874","market":"us","top_or_hot":-1,"title":"Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $7 million, an increase of 10.2% year-over-year.\nTherapeutic Device Revenue: $6.5 million, up 8.5% driven by PulseVet's 24.5% growth.\nDiagnostics Segment Revenue: Approximately $500,000, an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zomedica-corp-zom-q3-2024-190256725.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 03:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zomedica-corp-zom-q3-2024-190256725.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $7 million, an increase of 10.2% year-over-year.\nTherapeutic Device Revenue: $6.5 million, up 8.5% driven by PulseVet's 24.5% growth.\nDiagnostics Segment Revenue: Approximately $500,000, an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zomedica-corp-zom-q3-2024-190256725.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZOM","symbol_name":"Zomedica Pharmaceuticals Corp.","start_time":0,"source_url":"https://finance.yahoo.com/news/zomedica-corp-zom-q3-2024-190256725.html","article_id":"2482347874","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482347874","pubTimestamp":1731092576,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $7 million, an increase of 10.2% year-over-year.Therapeutic Device Revenue: $6.5 million, up 8.5% driven by PulseVet's 24.5% growth.Diagnostics Segment Revenue: Approximately $500,000, an increase of 38%.Gross Margin: 72.3%, higher than last year's 69%.Net Loss: $6.7 million, or 0.007 cents per share.Cash and Equivalents: $77.8 million at the end of the quarter.GuruFocus has detected 1 Warning Sign with ZOM.Zomedica Corp  reported a strong third quarter with double-digit top-line growth and solid gross margins.Zomedica Corp  experienced disruptions in the sales force due to unexpected medical leaves, impacting capital sales in the second quarter.A: We are confident in increasing revenues across all product segments. This is the 14th consecutive quarter of record revenue levels, and we expect this trend to continue into 2025. We will provide credible guidance in the new year. - Mike Zuehlke, Vice President of Finance, Corporate Controller","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"translate_title":"Zomedica Corp(ZOM)2024年第三季度收益看涨期权亮点：创纪录的收入和战略增长...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZOM":1},"content_text":"Revenue: $7 million, an increase of 10.2% year-over-year.\nTherapeutic Device Revenue: $6.5 million, up 8.5% driven by PulseVet's 24.5% growth.\nDiagnostics Segment Revenue: Approximately $500,000, an increase of 38%.\nGross Margin: 72.3%, higher than last year's 69%.\nOperating Expenses: $12.5 million, an increase of 21% year-over-year.\nNet Loss: $6.7 million, or 0.007 cents per share.\nNon-GAAP EBITDA Loss: $4.8 million.\nCash and Equivalents: $77.8 million at the end of the quarter.\nCash Used in Quarter: Approximately $5.1 million.\n\n\nWarning! GuruFocus has detected 1 Warning Sign with ZOM.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nZomedica Corp (ZOM) reported a strong third quarter with double-digit top-line growth and solid gross margins.\nThe company achieved a new revenue record for the third quarter at $7 million, reflecting over 10% growth year-over-year.\nZomedica Corp (ZOM) has expanded its global reach through strategic partnerships with distributors in new international markets, enhancing growth opportunities.\nThe diagnostics segment saw a 38% year-over-year revenue increase, driven by strong performance from the True Forma platform.\nThe company has made significant progress in operational efficiency, reducing operating expenses by over $900,000 compared to the previous quarter.\n\n Negative Points \n\nZomedica Corp (ZOM) experienced disruptions in the sales force due to unexpected medical leaves, impacting capital sales in the second quarter.\nThe company reported a net loss of $6.7 million for the quarter, compared to a net loss of $491,000 in the prior year.\nThere is a risk of potential delisting due to the stock price falling below $0.20 on a 30-day moving average.\nOperating expenses increased by 21% over the prior year, driven by non-recurring professional fees.\nThe company has not yet achieved cash flow breakeven, with a target of reaching this milestone at $50 million in annualized revenue.\n\n Q & A Highlights \nQ: How did the sales force recovery impact the quarter, and what is the outlook for growth in 2025? A: The sales force recovery positively impacted capital sales, with a 24% increase in PulseVet sales. We expect this trend to continue into the fourth quarter and beyond. For 2025, we plan to expand our sales presence and expect growth to accelerate. Once a new CFO is onboard, we will provide guidance in the new year. - Mike Zuehlke, Vice President of Finance, Corporate Controller\nQ: Can you provide any ballpark figures for revenue growth expectations pending the arrival of the new CFO? A: We are confident in increasing revenues across all product segments. This is the 14th consecutive quarter of record revenue levels, and we expect this trend to continue into 2025. We will provide credible guidance in the new year. - Mike Zuehlke, Vice President of Finance, Corporate Controller\nQ: Are the trends in cost of goods sold and operating expenses sustainable? A: We expect gross margins to remain around 70%, continuing the trend. Operating expenses as a percentage of revenue will continue to decline as we grow revenue and improve efficiencies. - Mike Zuehlke, Vice President of Finance, Corporate Controller\nQ: What is the timeline for reaching cash flow break-even and profitability? A: We expect to be cash flow positive at $50 million in annualized revenue, which is about 2% of our addressable market penetration. We previously aimed for 2026, which remains an aggressive but achievable goal. - Mike Zuehlke, Vice President of Finance, Corporate Controller\nQ: Is there any consideration for a stock buyback given the current share price? A: We believe a stock buyback is not in the best interest of all shareholders. We prefer to use our capital to fuel organic growth and potential acquisitions that are accretive to earnings. - Mike Zuehlke, Vice President of Finance, Corporate Controller\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482347874"}